Introduction

” See what you target, target what you see”     

NH TherAguix is a clinical stage pharmaceutical company developing innovative nanomedicine that improve radiation therapy benefits without modifying current clinical workflows. Our leading product, AGuIX®, is a nanoparticle designed to improve the localization of solid tumors and the outcomes of radiation therapy by a unique intravenous injection.

Currently, ~2/3 of cancer patients receive radiation therapy during their treatment. One of the main radiation therapy challenges is to deliver a sufficient radiation dose in the tumor while sparing the surrounding healthy tissues.

AGuIX®  plays a key role in imaging. Combined with MRI,  AGuIX® allows an increase of tumor contrast after injection, helping the physician to localize and delineate with accuracy the tumor region. AGuIX® also allows to personalize the radiation therapy treatment for each patient by determining the optimal moment to perform the irradiation.

AGuIX® plays a key role in radiation therapy. Combined with the radiation therapy, AGuIX® amplifies the radiation efficacy locally in the tumor by acting as a radioenhancer and a radiosensitizer. This technology allows to treat radioresistant cancers and to minimize the radiation therapy secondary effects by decreasing the dose to healthy tissues.

AGuIX® technology  is protected by 4 international patents and its efficacy has been demonstrated in 50+ scientific peer rerviewed publications .

Next step, the clinical trials We recently achieved a key milestone in our leading product development with the completion of cGMP production of 1000 vials of AGuIX® and the successful validation of the toxicity and stability tests required by the French-FDA.

The  first “in man injection” has been performed in July 2016 in partnership with the Grenoble University Hospital, France. Presently, 5 patients have been engaged in this trial.

We are currently seeking financing to meet the funding requirements to complete the upcoming Phase 1 program and produce new batches of drugs for Phase 2.